7398-42-7

Usage

Uses

Used in Pharmaceutical Industry:
4-(Bromomethyl)phenylacetic acid phenacylester is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to facilitate the formation of new chemical entities with potential therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(Bromomethyl)phenylacetic acid phenacylester serves as a precursor in the development of agrochemicals, such as pesticides and herbicides, due to its reactivity in creating biologically active molecules that can target specific pests or weeds.
Used in Organic Synthesis:
As a versatile building block, 4-(Bromomethyl)phenylacetic acid phenacylester is utilized in organic synthesis for the preparation of a wide range of organic compounds, including those with applications in materials science, dyes, and other specialty chemicals. Its bromomethyl and phenacylester functionalities allow for various chemical transformations, enhancing the compound's synthetic utility.

Upstream product

• 23786-13-2 methyl p-tolylacetate 
• 13737-36-5 4-bromophenylacetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 622-47-9 4-tolylacetic acid 
• 34472-65-6 (trimethylsilyl)diazomethane 
• 75-77-4 chloro-trimethyl-silane 
• 67-56-1 methanol 

Downstream Products

• 306271-94-3 3'',3'''-dichloro-5'',5'''-di(methoxycarbonyl)-4'',4'''-di[p-[(methoxycarbonyl)methyl]benzyloxy]-4',4'-diphenyl-3β-(3'-buten-1'-yl)cholestane 
• 193290-61-8 (4-cyanomethyl-phenyl)-acetic acid methyl ester 
• 155380-11-3 methyl 4-(hydroxymethyl)phenylacetate 
• 808753-05-1 (4-methylaminomethyl-phenyl)-acetic acid methyl ester 
• 369654-63-7 methyl 4-(N-2-picolylamino methyl) phenyl acetate 
• 187031-46-5 4-[(4-Phenyl-1-piperazinyl)methyl]phenylacetic acid hydrochloride 
• 187031-45-4 4-[[4-(2-Tolyl)-1-piperazinyl]methyl]phenylacetic acid hydrochloride 
• 187031-64-7 methyl 4-[[4-[phenyl-(2-pyridyl)methyl]-1-piperazinyl]methyl]phenylacetate 
• 187031-44-3 4-[[4-(2-Pyridyl)-1-piperazinyl]methyl]phenylacetic acid hydrochloride 
• 923565-72-4 1,1-dimethylethyl (2S)-2-methyl-4-((4-(2-(methyloxy)-2-oxoethyl)phenyl)methyl)-1-piperazinecarboxylate 

Relevant academic research and scientific papers

Preparation method of 4-bromomethyl methyl benzoate and derivative thereof

The invention provides a preparation method of methyl 4-bromomethyl benzoate and a derivative thereof, and the method comprises an esterification reaction for converting methyl benzoic acid into methyl benzoate and a bromination reaction for converting the methyl benzoate into the methyl 4-bromomethyl benzoate and the derivative thereof, the brominating agent for the bromination reaction is dibromohydantoin, and the structural formulas of the 4-bromomethyl methyl benzoate and the derivatives thereof are shown in the specification, wherein n1 is equal to 0, 1 or 2; n2 is equal to 1 or 2; according to the preparation method disclosed by the invention, the reaction time can be greatly shortened, the reaction yield is high, and the production efficiency is improved.

OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity

Nicotinamide phosphoribosyltransferase (NAMPT) is a key enzyme involved in the recycling of nicotinamide to maintain adequate NAD levels inside the cells. It has been postulated to be a pharmacological target, as it is overexpressed in cancer cells as well as in inflammatory diseases. We describe the synthesis and characterization of a novel class of one-digit nanomolar NAMPT inhibitors based on in vitro characterization. The most active compound tested, 30c, displayed activity in xenograft and allograft models, strengthening the potential of NAMPT inhibitors as antitumoral drugs. Furthermore, in the present contribution we describe the ability of 30c to significantly improve the outcome of colitis in mice. Given that this is the first report of an effect of NAMPT inhibitors in colitis, this result paves the way for novel applications for this class of compounds.

A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis. It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacological therapy to date. Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy. In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clinical trials combined with inhibition of soluble epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies. To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity. Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency. Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.

Synthesis and complexing properties of cyclic benzylopeptoids-a new family of extended macrocyclic peptoids

An efficient protocol for the solid-phase synthesis of six members of a new class of extended macrocyclic peptoids (based on ortho-, meta- and para-N-(methoxyethyl)aminomethyl phenylacetyl units) is described. Theoretical (DFT) and experimental (NMR) studies on the free and Na+-complexed cyclic trimers (3-5) and tetramers (6-8) demonstrate that annulation of the rigidified peptoids can generate new hosts with the ability to sequestrate one or two sodium cations with the affinities and stoichiometries defined by the macrocycle morphology. Ion transport studies have been also performed in order to better appreciate the factors promoting transmembrane cation translocation.

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).

NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

HETEROARYL INHIBITORS OF PDE4

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.

"INHIBITORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, COMPOSITIONS, PRODUCTS AND USES THEREOF"

Compounds of formula (I): able to inhibit nicotinamide phosphoribosyltransferase. The disclosure also relates to the use of compounds of formula (I) for treatment of pathological conditions in which NAMPT inhibition might be beneficial, such as acute and chronic inflammation, cancer and metabolic disorders.

COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF

The present invention relates generally to thienopyrimidine and thienopyridine class compounds and methods of use thereof. In particular embodiments, the present invention provides compositions comprising thienopyrimidine class compounds and methods of us